Cargando…
A high throughput bispecific antibody discovery pipeline
Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082157/ https://www.ncbi.nlm.nih.gov/pubmed/37029216 http://dx.doi.org/10.1038/s42003-023-04746-w |
_version_ | 1785021260227411968 |
---|---|
author | Segaliny, Aude I. Jayaraman, Jayapriya Chen, Xiaoming Chong, Jonathan Luxon, Ryan Fung, Audrey Fu, Qiwei Jiang, Xianzhi Rivera, Rodrigo Ma, Xiaoya Ren, Ci Zimak, Jan Hedde, Per Niklas Shang, Yonglei Wu, George Zhao, Weian |
author_facet | Segaliny, Aude I. Jayaraman, Jayapriya Chen, Xiaoming Chong, Jonathan Luxon, Ryan Fung, Audrey Fu, Qiwei Jiang, Xianzhi Rivera, Rodrigo Ma, Xiaoya Ren, Ci Zimak, Jan Hedde, Per Niklas Shang, Yonglei Wu, George Zhao, Weian |
author_sort | Segaliny, Aude I. |
collection | PubMed |
description | Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering for efficient generation of BsAb library cells, followed by functional interrogation at the single-cell level to identify and sort positive clones and downstream sequence identification and functionality characterization. Using a CD19xCD3 bispecific T cell engager (BiTE) as a model, we demonstrate that our single-cell platform possesses a high throughput screening efficiency of up to one and a half million variant library cells per run and can isolate rare functional clones at a low abundance of 0.008%. Using a complex CD19xCD3 BiTE-expressing cell library with approximately 22,300 unique variants comprising combinatorially varied scFvs, connecting linkers and VL/VH orientations, we have identified 98 unique clones, including extremely rare ones (~ 0.001% abundance). We also discovered BiTEs that exhibit novel properties and insights to design variable preferences for functionality. We expect our single-cell platform to not only increase the discovery efficiency of new immunotherapeutics, but also enable identifying generalizable design principles based on an in-depth understanding of the inter-relationships between sequence, structure, and function. |
format | Online Article Text |
id | pubmed-10082157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100821572023-04-09 A high throughput bispecific antibody discovery pipeline Segaliny, Aude I. Jayaraman, Jayapriya Chen, Xiaoming Chong, Jonathan Luxon, Ryan Fung, Audrey Fu, Qiwei Jiang, Xianzhi Rivera, Rodrigo Ma, Xiaoya Ren, Ci Zimak, Jan Hedde, Per Niklas Shang, Yonglei Wu, George Zhao, Weian Commun Biol Article Bispecific antibodies (BsAbs) represent an emerging class of immunotherapy, but inefficiency in the current discovery has limited their broad clinical availability. Here we report a high throughput, agnostic, single-cell-based functional screening pipeline, comprising molecular and cell engineering for efficient generation of BsAb library cells, followed by functional interrogation at the single-cell level to identify and sort positive clones and downstream sequence identification and functionality characterization. Using a CD19xCD3 bispecific T cell engager (BiTE) as a model, we demonstrate that our single-cell platform possesses a high throughput screening efficiency of up to one and a half million variant library cells per run and can isolate rare functional clones at a low abundance of 0.008%. Using a complex CD19xCD3 BiTE-expressing cell library with approximately 22,300 unique variants comprising combinatorially varied scFvs, connecting linkers and VL/VH orientations, we have identified 98 unique clones, including extremely rare ones (~ 0.001% abundance). We also discovered BiTEs that exhibit novel properties and insights to design variable preferences for functionality. We expect our single-cell platform to not only increase the discovery efficiency of new immunotherapeutics, but also enable identifying generalizable design principles based on an in-depth understanding of the inter-relationships between sequence, structure, and function. Nature Publishing Group UK 2023-04-07 /pmc/articles/PMC10082157/ /pubmed/37029216 http://dx.doi.org/10.1038/s42003-023-04746-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Segaliny, Aude I. Jayaraman, Jayapriya Chen, Xiaoming Chong, Jonathan Luxon, Ryan Fung, Audrey Fu, Qiwei Jiang, Xianzhi Rivera, Rodrigo Ma, Xiaoya Ren, Ci Zimak, Jan Hedde, Per Niklas Shang, Yonglei Wu, George Zhao, Weian A high throughput bispecific antibody discovery pipeline |
title | A high throughput bispecific antibody discovery pipeline |
title_full | A high throughput bispecific antibody discovery pipeline |
title_fullStr | A high throughput bispecific antibody discovery pipeline |
title_full_unstemmed | A high throughput bispecific antibody discovery pipeline |
title_short | A high throughput bispecific antibody discovery pipeline |
title_sort | high throughput bispecific antibody discovery pipeline |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082157/ https://www.ncbi.nlm.nih.gov/pubmed/37029216 http://dx.doi.org/10.1038/s42003-023-04746-w |
work_keys_str_mv | AT segalinyaudei ahighthroughputbispecificantibodydiscoverypipeline AT jayaramanjayapriya ahighthroughputbispecificantibodydiscoverypipeline AT chenxiaoming ahighthroughputbispecificantibodydiscoverypipeline AT chongjonathan ahighthroughputbispecificantibodydiscoverypipeline AT luxonryan ahighthroughputbispecificantibodydiscoverypipeline AT fungaudrey ahighthroughputbispecificantibodydiscoverypipeline AT fuqiwei ahighthroughputbispecificantibodydiscoverypipeline AT jiangxianzhi ahighthroughputbispecificantibodydiscoverypipeline AT riverarodrigo ahighthroughputbispecificantibodydiscoverypipeline AT maxiaoya ahighthroughputbispecificantibodydiscoverypipeline AT renci ahighthroughputbispecificantibodydiscoverypipeline AT zimakjan ahighthroughputbispecificantibodydiscoverypipeline AT heddeperniklas ahighthroughputbispecificantibodydiscoverypipeline AT shangyonglei ahighthroughputbispecificantibodydiscoverypipeline AT wugeorge ahighthroughputbispecificantibodydiscoverypipeline AT zhaoweian ahighthroughputbispecificantibodydiscoverypipeline AT segalinyaudei highthroughputbispecificantibodydiscoverypipeline AT jayaramanjayapriya highthroughputbispecificantibodydiscoverypipeline AT chenxiaoming highthroughputbispecificantibodydiscoverypipeline AT chongjonathan highthroughputbispecificantibodydiscoverypipeline AT luxonryan highthroughputbispecificantibodydiscoverypipeline AT fungaudrey highthroughputbispecificantibodydiscoverypipeline AT fuqiwei highthroughputbispecificantibodydiscoverypipeline AT jiangxianzhi highthroughputbispecificantibodydiscoverypipeline AT riverarodrigo highthroughputbispecificantibodydiscoverypipeline AT maxiaoya highthroughputbispecificantibodydiscoverypipeline AT renci highthroughputbispecificantibodydiscoverypipeline AT zimakjan highthroughputbispecificantibodydiscoverypipeline AT heddeperniklas highthroughputbispecificantibodydiscoverypipeline AT shangyonglei highthroughputbispecificantibodydiscoverypipeline AT wugeorge highthroughputbispecificantibodydiscoverypipeline AT zhaoweian highthroughputbispecificantibodydiscoverypipeline |